March 2019, Vol 12, Tenth Annual Payers' Guide

American Health & Drug Benefits is pleased to bring you the Tenth Annual Payers’ Guide to New FDA Approvals. As has now become a tradition of this publication, the goal of this Guide is to offer payers, providers, Pharmacy & Therapeutics committees, and other healthcare stakeholders an overview of the novel pharmaceuticals approved by the US Food and Drug Administration (FDA) in 2018.
Before we discuss the new indications for oncology therapies approved in 2018, a word about the novel drugs entering the market is in order, considering the new record set last year in drug approvals in the United States.
New Molecular Entities and New Biologic License Applications and New Biosimilars Approved in 2018
raine is a neurologic disease that affects approximately 37 million people in the United States and comprises several subtypes, including common migraine, complicated migraine, retinal migraine, chronic migraine, and cluster headaches.
Prostate cancer, the second most common type of cancer in men, is expected to affect 11.6% of all men during their lifetime. In fact, more than 3 million men in the United States are living with prostate cancer.
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in adults older than age 50 years. In the United States, approximately 11 million people have AMD.
More than 8 million people in the United States have psoriasis, which is a chronic disease associated with overactive immune and inflammatory responses.
In 1944, Jan G. Waldenström, MD, published his observations about a series of patients who presented with anemia, hepatosplenomegaly, hyperviscosity, bleeding, lymphoplasmacytic infiltrate in the bone marrow, and a large serum protein or “macroglobulin.”
Cutaneous squamous-cell carcinoma (CSCC) is a type of nonmelanoma skin cancer that affects the squamous cells in the middle and outer layers of the skin.
Hairy-cell leukemia (HCL) is a rare and indolent hematologic cancer. HCL, which is 4 to 5 times more frequent in men than in women, accounts for 2% of all leukemias.
Page 1 of 2
Results 1 - 10 of 17
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME